AOBiome company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aobiome.com

Stage

Corporate Minority | Alive

Total Raised

$33.71M

Last Raised

$30M | 5 yrs ago

About AOBiome

AOBiome is developing a transformative, new class of skin products based on ammonia-oxidizing bacteria (AOB). The company's products are designed to restore the natural balance of skin microbes that have been lost due to modern living practices, including use of soaps, and shampoos. AOB are ubiquitous bacteria that oxidize ammonia and urea, two components in sweat. The company is introducing a cosmetic product, AO+ Refreshing Cosmetic Mist, to improve skin look and feel. Separately, AOBiome plans to file an Investigational New Drug (IND) application with the FDA to pursue different formulations of AOB in therapeutic indications including acne, eczema, and diabetic ulcers.

AOBiome Headquarter Location

125 Cambridgepark Drive

Cambridge, Massachusetts, 02140,

United States

617-639-9980

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AOBiome

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AOBiome is included in 3 Expert Collections, including Beauty & Personal Care.

B

Beauty & Personal Care

1,852 items

Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.

O

Omics

275 items

D

Diabetes

1,750 items

AOBiome Patents

AOBiome has filed 31 patents.

The 3 most popular patent topics include:

  • Microbiology
  • Microbiomes
  • Bacteriology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/20/2018

1/18/2022

Acneiform eruptions, Glucocorticoids, Rare diseases, Pregnanes, Autoimmune diseases

Grant

Application Date

9/20/2018

Grant Date

1/18/2022

Title

Related Topics

Acneiform eruptions, Glucocorticoids, Rare diseases, Pregnanes, Autoimmune diseases

Status

Grant

Latest AOBiome News

11:30 EDT The Common Warts Market Size is Anticipated to Increase at a Significant CAGR of 14.41% in the 7MM During the Study Pe...

Apr 18, 2022

News provided by Share this article Share this article As per DelveInsight analysis, the Common Warts market will experience a significant impact in the coming years owing to the rising research and Common Warts prevalence along with the emergence of novel therapies from key Common Warts companies such as Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, and others. LAS VEGAS, April 18, 2022 /PRNewswire/ -- DelveInsight's Common Warts Market Insights  report provides a comprehensive understanding of current treatment practices, Common Warts emerging drugs, market share of individual therapies, and current and forecasted Common Warts market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan. Key Takeaways from the Common Warts Market As per DelveInsight's estimates, the Common Warts market size was USD 720.03 million in 2020 which is further expected to increase by 2032 in the 7MM. The US accounted for the maximum Common Warts market size compared to EU5 countries and Japan in 2020. The leading Common Warts companies such as Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Ltd, Aclaris Therapeutics, Inc., and others are developing therapies that are expected to launch their drugs in the Common Warts market in the coming years. Key Common Warts therapies in the pipeline include Candin, VBP-245, VP-102, CLS006, expected to bring a positive shift in the Common Warts market along with others. The key driver for the surge in Common Warts market size is the rise in the Common Warts prevalence in the 7MM. For further information on how the emerging therapies would shift the Common Warts market landscape download the sample at Common Warts Market Outlook Common Warts Overview Common Warts, also known as Verruca Vulgaris, are caused by non-malignant strains of the human papillomavirus (HPV). HPV Common Warts are typically benign lesions with a low risk of malignant transformation. They appear on the skin as rough, painless papules that can be grey or flesh-colored and are found in various body areas. Other HPV subtypes associated with cervical cancer are not the same strains that are linked with the causes of Verruca Vulgaris. Common Warts can be distinguished from other common types of warts, including genital, filiform, and plantar warts. Common Warts on hands and Common Warts on fingers are the most common, but they can also be found on the knees, ankles, arms, and legs. The Verruca Vulgaris symptoms include small, fleshy, grainy bumps, Flesh-colored, white, pink, or tan, Rough to the touch, Sprinkled with black pinpoints, which are small, clotted blood vessels. Common Warts Epidemiology Segmentation As per DelveInsight, the total Common Warts prevalent cases  were approx 2.7 million cases in the 7MM in 2020. Among EU5 countries, Germany has the highest Common Warts prevalence, while Spain had the lowest in 2020. The Common Warts Market Report  proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into: Diagnosed prevalent cases of Common Warts Gender-specific Prevalence of Common Warts Know how the epidemiological trends are going to look like in 2032 for the 7MM by downloading at Common Warts Epidemiological Insights Common Warts Market Common Warts account for nearly 70% of all viral warts and are more common in school-aged children. Despite the high incidence rate, the Common Warts treatment landscape is limited and ambiguous. Even though the majority of warts disappear on their own, some require treatment. The goal of treatment for Common Warts is to either destroy the wart or to stimulate an immune system response to fight the virus. It is possible that Verruca Vulgaris treatment will take weeks or months. Warts tend to recur or spread even after treatment. Salicylic acid, freezing (cryotherapy), laser treatment, and other antiviral products such as 5-flourouracil, imiquimod, and others dominate the current Common Wart treatment landscape. Furthermore, the current Common Warts market for wart-specific treatment is extremely limited. However, a few market participants have pipeline products in the disease indication. These include Candin, VBP-245, VP-102, and others. Common Warts Pipeline Therapies and Key Companies Candin: Nielsen Biosciences A-101: Aclaris Therapeutics, Inc. Discover more about therapy set to grab substantial Common Warts market share at Drugs for Common Warts   Common Warts Market Dynamics The current market landscape, governed with salicylic acid does not provide an opportunity for curing the warts, thus the recurrence is high. This challenge is dubbed as the Common Warts market driver for the continuing and future developmental activities for the indication. The Common Warts market's growth can be further attributed to the rising prevalence of human papillomavirus infections, recurrence of warts, and development of new products. Moreover, increasing awareness regarding warts is expected to foster market growth during the forecast period. Major pharmaceutical players are committed to developing the current pipeline to address the unmet needs and improvise the current Common Warts treatment landscape, further bolstering the overall revenue generation during the forecast period. As a result, the dynamics of the Common Warts market are anticipated to change in the coming years owing to the increasing awareness, the rising research and Common Warts prevalence along with the emergence of novel therapies. The expected launch of these therapies will fuel the Common Warts market size during the forecast period (2021–2032). Know more about which pharma player in the Common Warts market is set to emerge as the trendsetter at Common Warts Companies Scope of the Common Warts Market Report Study Period: 2019-2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Common Warts Companies: Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Maruho Co., Ltd, Aclaris Therapeutics, Inc., and others Key Pipeline Therapies: Candin, VBP-245, VP-102, CLS006, and others Therapeutic Assessment: Common Warts current marketed and emerging therapies Common Warts Market Dynamics:  Common Warts market drivers and barriers  Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Common Warts Market Access and Reimbursement Discover more about the future Common Warts market share of treatment therapies at Verruca Vulgaris Treatment Market Table of Contents Other Trending Dermatological Reports  Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Atopic Dermatitis companies such as Sanofi, Regeneron Pharmaceuticals, Pfizer, Japan Tobacco and Torii Pharmaceutical, Eli Lilly and Company, among others. Rosacea Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Rosacea companies such as Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, CAGE Bio Inc., among others. Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Acute Bacterial Skin and Skin Structure Infections companies such as Basilea Pharmaceutica, MicuRx Pharmaceuticals, TenNor Therapeutics Limited, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us

AOBiome Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AOBiome Rank

  • Where is AOBiome's headquarters?

    AOBiome's headquarters is located at 125 Cambridgepark Drive, Cambridge.

  • What is AOBiome's latest funding round?

    AOBiome's latest funding round is Corporate Minority.

  • How much did AOBiome raise?

    AOBiome raised a total of $33.71M.

  • Who are the investors of AOBiome?

    Investors of AOBiome include iCarbonX, Wild Ventures and JLabs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.